Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.83 |
| ▸ | FAAH | O00519 | 14/20 | 0.83 |
| ▸ | RAF1 | P04049 | 1/20 | 0.83 |
| ▸ | AADAC | P22760 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420136 | 1.00 | EPHX2 (0.83) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL15612039 | 0.91 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL15271834 | 0.91 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL15612306 | 0.91 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL23340590 | 0.90 | EPHX2 (0.71) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL15612815 | 0.89 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL4256246 | 0.89 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL4256244 | 0.89 | EPHX2 (1.00) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL17420143 | 0.89 | EPHX2 (0.79) | EPHX2FAAHRAF1AADAC | |
| SCHEMBL17420144 | 0.89 | EPHX2 (0.79) | EPHX2FAAHRAF1AADAC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | claimed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | claimed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | claimed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | claimed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2017214394-A2 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | EPHX2 4/4885FAAH 61/4885RAF1 3438/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885FAAH 33/4885RAF1 3702/4885 |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885RAF1 4122/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 13/4885RAF1 3766/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885RAF1 4122/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885RAF1 2980/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885FAAH 33/4885RAF1 3702/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885FAAH 213/4885RAF1 4737/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885FAAH 223/4885RAF1 4122/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | EPHX2 4/4885FAAH 61/4885RAF1 3438/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | EPHX2 3353/4885FAAH 4685/4885RAF1 1979/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885FAAH 13/4885RAF1 3766/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885FAAH 1/4885RAF1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.